All In Biotech

Drug Trial Radar · NCT07883928

Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,806 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,806

Planned (sponsor's estimate)

Start

Oct 12, 2026

Primary completion

Mar 2028

Study completion Aug 2028

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older. The study will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control. After providing written informed consent, participants will undergo screening to determine whether they are eligible. Eligible participants will be randomly assigned to a study group and receive a single dose of the investigational product on Day 0. Participants will record solicited adverse events in a subject diary from Day 0 through Day 7. The study site will contact participants by telephone on Day 7 to check on adverse events, concomitant medications, and diary completion. On Day 28, participants will visit the study site for safety follow-up and blood sampling. Participants will be monitored for serious adverse events for 6 months.

Conditions

  • Influenza A, Influenza B
  • Influenza Vaccination

Interventions

  • vaccination of GC3114BBiological

    influenza vaccination

  • Vaccination of EflueldaBiological

    influenza vaccination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the immunogenicity of GC3114BTime frame: Day 28 following IP vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.